WIL Research Acquires Ricerca Facility in Lyon, France
News Jun 21, 2013
“As we listened to our clients and analyzed emerging trends in the pharmaceutical marketplace, it became clear that expansion of our biologic capabilities in Europe was the right move for us,” said David Spaight, WIL Research’s Chairman and Chief Executive Officer. “The Lyon operation leverages our existing capabilities in the United States and the Netherlands and creates a powerful new platform to deliver exceptional value to our clients. This definitive acquisition will double our capacity in Europe, strengthen our offerings to clients and enable WIL Research to accelerate the healthy growth rate we have achieved over the past three years in a challenging market environment.”
Dr. Michael Placke, President, Ricerca Biosciences LLC, explained, “This divestiture will fund significant capital investment into our Concord, Ohio business allowing us to expand and re-invigorate our integrated drug development services in chemical development, drug substance production, and drug safety and metabolism”.
Renamed WIL Research Europe - Lyon, the lab will retain its approximately 280 employees. Long-time Managing Director of the facility, Stéphane Bulle, will continue to lead the site and keep his current senior leadership team intact.
With the expansion, WIL Research strengthens its global position as a highly credible player serving the pharmaceutical and chemical industries and its commitment to client needs for nimbleness and customized services.
“While this acquisition expands our integrated safety assessment and associated services for pharmaceutical companies, it also enables us to enhance our focus on the chemical and agrochemical industries via our expert scientific staff in Den Bosch, The Netherlands,” added Spaight.
Over the past 45 years, the Lyon facility has developed a strong scientific reputation with European pharmaceutical clients in safety pharmacology and specialized services including continuous infusion and developmental and reproductive toxicology.
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Cancer Cells Force Normal Cells to Act Like Viruses, Helping Tumors SpreadNews
Researchers reveal how cancer cells force normal cells to act like viruses – allowing tumors to grow, resist treatment, and spread.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018